* If you want to update the article please login/register
Moreover, the SPOP mutation sites are found in a very short area with multiple lysine residues, raising significant difficulties for bottom-up proteomics analysis of the SPOP mutations. PRISM -SRM mass spectrometry assays have been developed to analyze wild-type SPOP protein and 11 prostate cancer-derived SPOP mutations in response to this problem. Application of these SRM assays to analyze HEK293T cells with and without expression of the three most common SPOP mutations in prostate cancer led to the confident identification of all three SPOP mutations in corresponding positive cell lines, but not in the negative cell lines. The expression of the F133V mutation and wild-type SPOP was at much lower level compared to those of F102C and Y87N mutations; however, at present, it is unknown if it also influences the SPOP protein's activity.
Source link: https://www.osti.gov/biblio/1406773
Primary prostate cancer heterogeneity in Tumour heterogeneity is a well-established phenomenon. We describe the precise direction of metastatic disease in four lethal prostate cancer patients using whole-genome and ultra-deep targeted sequencing of longitudinally collected primary and metastatic tumors. As a result, an enrichment of TP53 mutations has been found in metastasis, as shown by further sequencing of metastases from 19 patients, indicating that the proliferation of subclones with metastatic potential, which we can detect in the blood.
Source link: https://www.osti.gov/biblio/1236642
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions